US Military Cancer Institute partners on cancer trial

February 16, 2007

Rockville, MD--The United States Military Cancer Institute (USMCI) and Generex Biotechnology Corporation announced that they have entered into a Phase II clinical trial for a novel peptide vaccine for breast cancer. The immunotherapeutic vaccine, AE37, is being developed by Generex's Antigen Express subsidiary in the U.S. The study will be conducted in conjunction with USMCI's Clinical Trials Group.

The trial will be a randomized, multi-center study among patients who have completed standard therapy for node-positive or high-risk node-negative breast cancer expressing at least low levels of the HER-2/neu oncogene. These patients are at an increased risk for recurrence. The endpoint for the study will be a 50 percent reduction in rate of relapse of the disease at the two-year point. USMCI and Generex initiated a Phase I trial of AE37in April 2005, the results of which showed good immunostimulatory activity, safety and tolerance.

AE37 is being tested under the direction of Colonel George Peoples, M.D., at Brooke Army Medical Center. The study is a collaboration among USMCI, the Uniformed Services University of the Health Sciences (USU) and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). Antigen Express entered into a Clinical Trial Agreement with HJF to enable work with Peoples, USMCI and USU, with the goal of advancing the company's HER-2/neu vaccine efforts for breast cancer.

The immunotherapeutic agent being developed by Antigen Express is a peptide derived from a tumor-associated protein that has been modified to enhance the stimulation of CD4+ T helper cells. The target protein is encoded by the HER-2/neu oncogene, which has been found to be over-expressed in tumors from a variety of cancers, including breast, ovarian, prostate, lung, colon, stomach and pancreatic cancers. Antigen-specific stimulation of T helper cells, which occurs after immunization with AE37, has been shown in prior studies to be critical for the immune system to mount an effective anti-tumor response.
-end-
USMCI, a USU program, is a tri-service initiative that coordinates and supports multi-institutional cancer research within the DoD system. The Institute has many initiatives under way, including a new BioSpecimen Network and a Tissue Microarray Core facility. When the new Walter Reed National Military Medical Center opens in 2011, it will serve as the USMCI Clinical Research Cancer Center, and as the focal point for cancer research in the military. USMCI operates with Congressional funding and is a collaborative effort among Walter Reed Army Medical Center, the National Naval Medical Center, the Armed Forces Institute of Pathology and HJF.

USU (www.usuhs.edu) is a fully accredited federal school of medicine and graduate school of nursing. The University is recognized worldwide as a preeminent center for the study of military and emergency medicine, preventive medicine, tropical diseases, disaster medicine and adaptation to extreme environments.

HJF (www.hjf.org) is a private, not-for-profit organization chartered by Congress to support military medical research and education at USU and throughout military medicine. HJF's technology transfer staff encourages scientists and private industry to collaborate on research and development projects, with the goal of making innovative medical technologies available for clinical use.

Generex (www.generex.com) is engaged in the research and development of drug delivery systems and technologies. Antigen Express (www.antigenexpress.com) is a wholly owned subsidiary of Generex, and the company's core platform technologies comprise immunotherapeutics for the treatment of malignant, infectious, allergic and autoimmune diseases.

Henry M. Jackson Foundation for the Advancement of Military Medicine

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.